Wave Life Sciences, Inc.
For the period ended Sep 30, 2026. Filed Oct 27, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Oct 27, 2026
WVE$3.41-2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Unaudited Consolidated Statements of Cash Flows
(In thousands)
| Nine Months Ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities | ||
| Net loss | $(157,354) | $(151,199) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Amortization of right-of-use assets | 4,385 | 3,994 |
| Depreciation of property and equipment | 2,579 | 2,596 |
| Accretion of investment premium | (596) | — |
| Net realized loss on sale of marketable securities | 4 | — |
| Stock-based compensation expense | 30,084 | 17,621 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | (10,724) | (8,578) |
| Prepaid expenses | (3,161) | 2,891 |
| Other assets | (2,129) | 4,766 |
| Accounts payable | 3,519 | (1,717) |
| Accrued expenses and other current liabilities | (4,585) | (4,594) |
| Deferred revenue | (30,789) | (13,865) |
| Operating lease liabilities | (4,510) | (5,632) |
| Net cash used in operating activities | (173,277) | (153,717) |
| Cash flows from investing activities | ||
| Purchases of property and equipment | (1,337) | (719) |
| Purchases of marketable securities | (236,499) | — |
| Sales and maturities of available-for-sale debt securities | 3,085 | — |
| Net cash used in investing activities | (234,751) | (719) |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock pursuant to the “at-the-market” equity program, net of offering costs | — | 42,573 |
| Proceeds from the exercise of stock options | 2,352 | 5,086 |
| Proceeds from the ESPP | 938 | 881 |
| Net cash provided by financing activities | 3,290 | 48,540 |
| Effect of foreign exchange rates on cash, cash equivalents, and restricted cash | (6) | 72 |
| Net decrease in cash, cash equivalents, and restricted cash | (404,744) | (105,824) |
| Cash, cash equivalents, and restricted cash, beginning of period | 605,874 | 305,838 |
| Cash, cash equivalents, and restricted cash, end of period | $201,130 | $200,014 |
| Supplemental disclosure of cash flow information | ||
| Operating lease right-of-use assets obtained in exchange for operating lease liabilities (See Note 2) | $(30,015) | $— |
Wave Life Sciences, Inc.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.